

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Applicant: Jay M. Meythaler et al.  
Serial No.: 10/049,328 Group Art Unit: 1614  
Filing Date: May 15, 2002 Examiner: Donna A. Jagoe  
For: USE OF GABA AGONISTS FOR TREATMENT OF SPASTIC  
DISORDERS, CONVULSIONS, AND EPILEPSY

---

**STATEMENT OF THE SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Please enter the following statement of record of interview with regard to the above-referenced application. Applicant hereby provides the following information with respect to the telephonic interview of June 28, 2007 between Examiner Jagoe, SPE Marschel, and Applicant's representative, Avery Goldstein. No demonstrations were performed. The interview included a discussion of claim 12 and Applicant's efforts to explicitly exclude 4-chlorophenyl-5-fluoro-2-hydroxyphenylmethanone from the claim. Applicant reiterated that administration of GABAamide precludes the side effects associated with the 4-chlorophenyl-5-fluoro-2-hydroxyphenylmethanone metabolite of progabide. No agreement was asked for and as such is inapplicable. The substance of this interview is incorporated in the RCE filed in July 2007.

Applicant believes the above summary is in compliance with 37 CFR 1.133. Entry of this summary is hereby requested.

Respectfully submitted,

*Dated: 7-23-07*

/Avery Goldstein/  
Avery Goldstein  
Registration No. 39,204  
Gifford, Krass, Groh, Sprinkle,  
Anderson & Citkowski, P.C.  
2701 Troy Center Drive, Suite 330  
P.O. Box 7021  
Troy, MI 48007-7021  
(248) 647-6000

Attorney for Applicant

ANG